Sunday November 22 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

ChemoCentryx, Inc.

ChemoCentryx is a focused pharmaceutical company creating first-in-class, orally available medicines for autoimmune diseases, inflammatory disorders and oncology.
By leveraging our pioneering expertise in the field of chemokine research, ChemoCentryx has generated a broad portfolio of medicines targeting the chemokine system, with six product candidates currently in pre-clinical and clinical stages of development. Our pipeline includes: Traficet-EN™ currently in Phase II clinical studies and initially being developed for inflammatory bowel disease. Traficet-EN targets a chemokine receptor called CCR9, which regulates the trafficking of inflammatory cells to the digestive tract. In a separate program, ChemoCentryx intends to take a new drug candidate for multiple sclerosis and cardiovascular disease, targeting the receptor CCR2, into clinical trials this year. Also, two promising compounds targeting novel chemokine receptors are in development for the treatment of cancers. Lastly, ChemoCentryx has two partnered programs. A CCR1 antagonist is being co-developed with Forest Laboratories for autoimmune disorders and CXCR3 receptor antagonists are being developed by ChemoCentryx's partner, Amgen-SF (formerly Tularik).


Contact Details:
850 Maude Avenue
Mountain View
California
94043
United States of America
Tel:650-210-2900
Fax:650-210-2910
Email:
WWW:

www.chemocentryx.com/




Loading...

Press Releases on ChemoCentryx, Inc.:

BioPortfolio Logo
PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference 1st June, 2009 ChemoCentryx, Inc.
Oral CCR9 Antagonist Demonstrates Clinical Efficacy with Favorable Tolerability Profile MOUNTAIN VIEW, Calif., June 1 /PRNewswire/ -- ChemoCentryx, Inc., announced that Phase II/III clinical data
ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 19th May, 2009 ChemoCentryx, Inc.
First-in-class Oral Therapeutic for IBD with Novel Mode of Action MOUNTAIN VIEW, Calif., May 19 /PRNewswire/ -- ChemoCentryx, Inc., today announced that data from the company's PROTECT-1 (the
ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist 5th May, 2009 ChemoCentryx, Inc.
Development Candidate Triggers Milestone Payment from GlaxoSmithKline MOUNTAIN VIEW, Calif., May 5 /PRNewswire/ -- ChemoCentryx, Inc., today announced that it has identified an orally
Solexa Names Linda Rubinstein Vice President And CFO 1st January, 1970 Solexa
Solexa Names Linda Rubinstein Vice President And CFO HAYWARD, Calif. (March 30, 2005) – Solexa, Inc. (NASDAQ: SLXA) today announced the

BioNews Results for ChemoCentryx, Inc.:

Guru Stocks at 52-Week Low: Genzyme Corp, Apollo Group Inc, Ralcorp Holdings Inc, Aqua America Inc, MetroPCS C
Guru Focus:  Nov 16 2009 3:51AM Matching: inc
AngioDynamics, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new report released
PR inside:  Nov 16 2009 5:28AM Matching: inc
Antares Pharma, Inc. - Medical Equipment - Deals and Alliances Profile - new report released
PR inside:  Nov 16 2009 5:23AM Matching: inc
Antares Pharma, Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new report
PR inside:  Nov 16 2009 5:23AM Matching: inc
AspenBio Pharma, Inc. - Medical Equipment - Deals and Alliances Profile - new report released
PR inside:  Nov 16 2009 4:58AM Matching: inc
Promote your company here: BioNewsCast - Press Release Distribution

View more ChemoCentryx, Inc. news.

ChemoCentryx, Inc. Patents:

US Patent No.Title
7589199 Substituted piperazines
7335653 Bis-aryl sulfonamides
7282338 Cell migration assay
7262204 Modulation of CCR4 function
7253007 Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors

View more ChemoCentryx, Inc. patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 512 times since April 2007, the link to the organisation's website has been followed 69 times

Recent Search Terms used to find this page: chemocentryx logo | ChemoCentryx antagonist | chemocentryx | Chemocentryx | chemocentryx | chemocentryx | chemocentryx | chemocentryx | chemocentryx | us 7524845 | .

Search for more companies in Mountain View

Search for more companies in California



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for ChemoCentryx, Inc.

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.